ATHA Stock Analysis: Buy, Sell, or Hold?
ATHA - Athira Pharma, Inc. Common Stock
$6.75
-0.44 (-6.12%)
▼
5d:
-3.02%
30d:
+73.75%
90d:
+72.19%
HOLD
MODERATE Confidence
Analysis Updated: Jan 9, 2026 12:00 AM ET
Earnings: Feb 26, 2026
0d
Get Alerted When ATHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ATHA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ATHA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ATHA is currently trading at $6.75, which is considered fair based on recent price action.
Technical Outlook: Technically, ATHA is in a strong uptrend. Immediate support is located at $6.41, while resistance sits at $7.77. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $4.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ATHA is in a strong uptrend. Immediate support is located at $6.41, while resistance sits at $7.77. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $4.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
56/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
53.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BEARISH: Downward momentum (-6.1%)
- BEARISH: Trading 40.7% above Wall St target ($4.00)
Support & Resistance Levels
Support Level
$6.41
Resistance Level
$7.77
Current Trend
Strong Uptrend
Technical data as of
Jan 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.34
Wall Street Target
$4.00
(-40.7%)
Share & Embed Analysis
Last updated: May 08, 2026 9:08 PM ET
Data refreshes hourly during market hours. Next update: 10:08 PM
Data refreshes hourly during market hours. Next update: 10:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$408 | 58 HOLD |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$230 | 55 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 62 BUY |
